Wegovy Tablet Prescriptions Rise Steadily as Foundayo Gains Early Traction

In the twentieth week of 2025, prescription statistics for oral semaglutide weight management tablets kept rising. The total number of prescriptions filled increased from 107,029 the previous week to 109,777. The steady demand for oral treatments in the treatment of obesity is shown in the incremental gain. Physicians observe that patients are choosing oral alternatives over conventional injectables more and more.

A competing oral weight-loss drug also made noticeable progress over the same period. The number of prescriptions rose from 2,067 to 2,520 the previous week. Although the raw numbers are still far below the market leader, the trajectory indicates early market uptake. This development also indicates a growing interest in new therapeutic approaches.

There is a serious methodological problem with both datasets. Online pharmacies, digital platforms, and direct methods of dispensing are not included in the stated figures. Consequently, the tracking data only reflects a portion of the actual weekly usage. Analysts must interpret these specific metrics carefully.

The recorded and actual prescription volume still differ significantly. Corporate management disclosed that more than 200,000 prescriptions are written every week during a recent financial results presentation. Independent data collected during comparable periods accounted for around half of that amount. Because of this, direct pharmacy channels now account for a large percentage of therapeutic dispensing.

Both oral medications have been classified as prescription-only by federal regulatory bodies. The best oral formulation joins an already-approved injectable drug for long-term weight control. Patients must meet specific criteria, such as having a weight-related comorbidity that has been documented. Meanwhile, rivalry outside of the injectable industry is increased by the more current agent.

The parallel growth patterns of both agents point to a broader market expansion. True market dynamics currently favor sector-wide development over direct share substitution. However, it will be necessary to closely monitor the competitive dynamics in oral medication for weight loss. Clinicians, payers, and healthcare stakeholders must continuously evaluate these developments.